JAK2 and myeloproliferative disorder: Whereas MPN patients typically exhibit activated OXPHOS and mTORC1 signaling pathways and enhanced mitochondrial activities in PLTs, both leading to PLT hyperactivity [17], Jak2-R1063H-positive PLTs metabolic abnormalities were associated with fatty acid metabolism.